Your browser doesn't support javascript.
loading
Long-Term Patient-Reported Arm Symptoms in Breast Cancer Survivors.
Laws, Alison; Lagendijk, Mirelle; Grossmith, Samantha; Hughes, Melissa; Lin, Nancy U; Mittendorf, Elizabeth A; Eliassen, A Heather; King, Tari A; Dominici, Laura S.
Afiliação
  • Laws A; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
  • Lagendijk M; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
  • Grossmith S; Harvard Medical School, Boston, MA, USA.
  • Hughes M; Department of Surgery, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Lin NU; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
  • Mittendorf EA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
  • Eliassen AH; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
  • King TA; Harvard Medical School, Boston, MA, USA.
  • Dominici LS; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Ann Surg Oncol ; 31(3): 1623-1633, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38071708
ABSTRACT

BACKGROUND:

Understanding long-term arm symptoms in breast cancer survivors is critical given excellent survival in the modern era.

METHODS:

This cross-sectional study included patients treated for stage 0-III breast cancer at our institution from 2002 to 2012. Patient-reported arm symptoms were collected from the EORTC QLQ-BR23 questionnaire. We used linear regression to evaluate adjusted associations between locoregional treatments and the continuous Arm Symptom (AS) score (0-100; higher score reflects more symptoms).

RESULTS:

A total of 1126 patients expressed interest in participating and 882 (78.3%) completed the questionnaire. Mean time since surgery was 10.5 years. There was a broad distribution of locoregional treatments, including axillary lymph node dissection (ALND) in 37.1% of patients, mastectomy with reconstruction in 36.5% of patients, and post-mastectomy radiation in 38.2% of patients. Overall, 64.3% (95% confidence interval [CI] 61.1-67.4%) of patients reported no arm symptoms, 17.0% (95% CI 14.7-19.6%) had one mild symptom, 9.4% (95% CI 7.7-11.5%) had two or more mild symptoms, and 9.3% (95% CI 7.6-11.4%) reported one or more severe symptoms. Adjusted AS scores were significantly higher with ALND versus sentinel node biopsy (ß 3.5, p = 0.01), and with autologous reconstruction versus all other breast/reconstructive surgery types (ß 4.5-5.5, all p < 0.05). There was a significant interaction between axillary and breast/reconstructive surgery, with the greatest effect of ALND in those with mastectomy with implant (ß 9.7) or autologous (ß 5.7) reconstruction.

CONCLUSIONS:

One in three patients reported arm symptoms at a mean of 10 years from treatment for breast cancer, although rates of severe symptoms were low (<10%). Attention is warranted to the arm morbidity related to both axillary and breast surgery during treatment counseling and survivorship.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Sobreviventes de Câncer / Linfedema Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Sobreviventes de Câncer / Linfedema Idioma: En Ano de publicação: 2024 Tipo de documento: Article